CD19 and acute lymphoblastic leukemia: According to the accumulating evidence, the median event-free survival (EFS) time following CD19 CAR-T treatment among R/R B-ALL, B-NHL and B-CLL patients has been estimated to be 6-12 months (2–4), 3-6 months (5–7), and 3-12 months (8–10), respectively.